Sirolimus As Frontline Therapy for -mutated Histiocytic Sarcoma

Overview

Journal Haematologica

Specialty Hematology

Date 2022 Dec 7

PMID 36475523

Authors

Karan L Chohan

Jithma P Abeykoon

Jason R Young

W Oliver Tobin

Mathew J Koster

Mithun V Shah

Jay H Ryu

Robert Vassallo

Karen L Rech

Aishwarya Ravindran

Gaurav Goyal

Ronald S Go

N Nora Bennani

Affiliations

Soon will be listed here.

References

Massoth L, Hung Y, Ferry J, Hasserjian R, Nardi V, Nielsen G . Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma. Oncologist. 2021; 26(7):e1263-e1272. PMC: 8265357. DOI: 10.1002/onco.13801. View

Gianfreda D, Nicastro M, Galetti M, Alberici F, Corradi D, Becchi G . Sirolimus plus prednisone for Erdheim-Chester disease: an open-label trial. Blood. 2015; 126(10):1163-71. DOI: 10.1182/blood-2015-01-620377. View

Carrasco D, Fenton T, Sukhdeo K, Protopopova M, Enos M, You M . The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. Cancer Cell. 2006; 9(5):379-90. DOI: 10.1016/j.ccr.2006.03.028. View

Hong J, Kahan B . Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation. 2000; 69(10):2085-90. DOI: 10.1097/00007890-200005270-00019. View

Kahan B . Sirolimus: a comprehensive review. Expert Opin Pharmacother. 2002; 2(11):1903-17. DOI: 10.1517/14656566.2.11.1903. View

Hornick J, Jaffe E, Fletcher C . Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol. 2004; 28(9):1133-44. DOI: 10.1097/01.pas.0000131541.95394.23. View

Shanmugam V, Griffin G, Jacobsen E, Fletcher C, Sholl L, Hornick J . Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. Mod Pathol. 2019; 32(6):830-843. DOI: 10.1038/s41379-018-0200-x. View

Saxton R, Sabatini D . mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017; 169(2):361-371. DOI: 10.1016/j.cell.2017.03.035. View

Gounder M, Solit D, Tap W . Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. N Engl J Med. 2018; 378(20):1945-1947. PMC: 6062005. DOI: 10.1056/NEJMc1511490. View

10.

Yin Y, Shen W . PTEN: a new guardian of the genome. Oncogene. 2008; 27(41):5443-53. DOI: 10.1038/onc.2008.241. View

11.

Skala S, Lucas D, Dewar R . Histiocytic Sarcoma: Review, Discussion of Transformation From B-Cell Lymphoma, and Differential Diagnosis. Arch Pathol Lab Med. 2018; 142(11):1322-1329. DOI: 10.5858/arpa.2018-0220-RA. View

12.

Egan C, Nicolae A, Lack J, Chung H, Skarshaug S, Pham T . Genomic profiling of primary histiocytic sarcoma reveals two molecular subgroups. Haematologica. 2019; 105(4):951-960. PMC: 7109753. DOI: 10.3324/haematol.2019.230375. View

13.

Idbaih A, Mokhtari K, Emile J, Galanaud D, Belaid H, de Bernard S . Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology. 2014; 83(16):1478-80. DOI: 10.1212/WNL.0000000000000880. View

14.

Kommalapati A, Tella S, Durkin M, Go R, Goyal G . Histiocytic sarcoma: a population-based analysis of incidence, demographic disparities, and long-term outcomes. Blood. 2017; 131(2):265-268. PMC: 5757688. DOI: 10.1182/blood-2017-10-812495. View

15.

Komiya T, Blumenthal G, DeChowdhury R, Fioravanti S, Ballas M, Morris J . A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in . Oncologist. 2019; 24(12):1510-e1265. PMC: 6975943. DOI: 10.1634/theoncologist.2019-0514. View